Screening for Type 2 Diabetes > Patient Education Author: Lorraine Lipscombe, MD, FRCPC; Denice S. Feig, MD, MSc, FRCPC
Editorial changes - 2009-05-01
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Screening Tests
Effectiveness/Harms of Early Treatment
Direct Evidence that Screening Reduces Adverse Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines
Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Recommendation
Know that diabetes education strategies involving patient collaboration have been shown to improve glycemic control, weight loss, and lipid profiles in patients with type 2 diabetes.A

Evidence:

  • A systematic review of the literature identified 72 randomized controlled trials of patient self-management training strategies for type 2 diabetes patients. These trials included education on self-care, dietary modifications, and increased physical activity. Interventions using regular reinforcement throughout follow-up and those involving patient collaboration were most effective at improving glycemic control and weight and lipid profiles (142).
  • A meta-analysis of 31 randomized controlled trials of self-management education for type 2 diabetes patients found that education strategies immediately reduce HbA1c by a mean 0.76% (0.34% to 1.18%), and by a mean of 0.26% (0.05% to 0.48%) after 4 months or more. The benefits of diabetes education are related to the amount of contact time between patient and educator, with an estimated 1% decrease in HbA1c for every 23.6 hours of contact (143).

Comments:

  • None.

FAQs
Denice S. Feig, MD, MSc, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lorraine Lipscombe, MD, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sonal Singh, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.